The Committee for Medicinal Products for Veterinary Use (CVMP) met on 10-12 February 2026 and adopted a positive opinion on the marketing authorization of Emepax (maropitant) for dogs.[5] The drug is indicated for the prevention of chemotherapy-induced nausea, the prevention of vomiting caused by motion sickness, as well as the prevention and treatment of vomiting in combination with maropitant injectable solution and other supportive measures in dogs.[5] The agenda of the meeting also included the assessment of Senvelgo (velagliflozin), Solensia (frunevetmab) and Librela (bedinvetmab).[5] Post-authorization measures and changes related to drug quality were discussed.[5] Other points included fuzapladib sodium for the treatment of clinical manifestations of acute pancreatitis in dogs and variation of qualitative changes for Enteroporc Coli AC against colibacillosis in pigs.[5] The CVMP planned to receive opinions, evaluation reports and product information.[5]